BiTEs: bispecific antibody constructs with unique anti-tumor activity (Q36280826)

13 August 2017

1 reference

title

BiTEs: bispecific antibody constructs with unique anti-tumor activity (English)

1 reference

13 August 2017

1 reference

5

Patrick A Baeuerle

1 reference

13 August 2017

Evelyn Wolf

1

1 reference

13 August 2017

Robert Hofmeister

series ordinal

2

1 reference

13 August 2017

Peter Kufer

series ordinal

3

1 reference

13 August 2017

Bernd Schlereth

series ordinal

4

1 reference

13 August 2017

1 September 2005

1 reference

13 August 2017

1 reference

13 August 2017

10

1 reference

13 August 2017

18

1 reference

13 August 2017

1237-1244

1 reference

Improving the efficacy of antibody-based cancer therapies

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

A revival of bispecific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Antigen-processing machinery breakdown and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Selective MHC expression in tumours modulates adaptive and innate antitumour responses

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2‐microglobulin inactivation in MSI‐positive tumors and LMP7/TAP2 downregulation in MSI‐negative tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

MHC class I antigens, immune surveillance, and tumor immune escape.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

A New Twist on Autologous Cancer Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Natural killer cells and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Monoclonal antibodies in cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

3 Protein engineering of single-chain Fv analogs and fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Production and characterization of bispecific single-chain antibody fragments.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Cytosolic delivery of granzyme B by bacterial toxins: evidence that endosomal disruption, in addition to transmembrane pore formation, is an important function of perforin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Costimulation: building an immunological synapse

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

The immunological synapse of CTL contains a secretory domain and membrane bridges.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903554-3

7 January 2021

10.1016/S1359-6446(05)03554-3

Identifiers

DOI

1 reference

13 August 2017

1 reference